<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953261</url>
  </required_header>
  <id_info>
    <org_study_id>5190041</org_study_id>
    <nct_id>NCT03953261</nct_id>
  </id_info>
  <brief_title>Effect of Curcumin on Systemic Lupus Erythematosus</brief_title>
  <official_title>Effect of Curcumin on Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigator initiated study is to determine the efficacy of curcumin on
      disease activity of subjects with systemic lupus erythematous. Curcumin has been found to
      have anti-inflammatory effects and has been found to improve disease activity in lupus
      patients. In addition, subjects with rheumatoid arthritis as well as osteoarthritis have also
      found benefit for their disease activity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in SLEDAI</measure>
    <time_frame>90 days</time_frame>
    <description>Number of participants with change in SLEDAI by 2 points by Day 90</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin supplement</intervention_name>
    <description>Intervention is 2 grams of curcumin supplement per day</description>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated informed consent form

          -  Stated willingness to comply with all study procedures and availability for the
             duration of the study

          -  Male or female, aged 18 or older

          -  Diagnosed with Systemic Lupus Erythematous according to the 2012 Systemic Lupus
             International Collaborating Clinics Classification Criteria.

          -  SLEDAI score of 6 or higher

          -  Ability to take oral medication and be willing to adhere to the study drug regimen

        Exclusion Criteria:

          -  Inability to provide written consent for study participation

          -  Use of curcumin supplements within 30 days of enrollment of study

          -  Liver function disorders (AST/ALT &gt; 2.5x upper limit of normal)

          -  Pregnancy or lactation

          -  Known allergic reactions to turmeric

          -  Subjects who are admitted for recent hospitalization within past 60 days

          -  Treatment with another investigational drug or other intervention within past 60 days

          -  Subjects with end stage renal disease on dialysis

          -  Subjects who lack the ability to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vaneet Sandhu, MD</last_name>
    <phone>909.558.4911</phone>
    <email>vksandhu@llu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Micah Yu, MD</last_name>
    <phone>909.558.4911</phone>
    <email>micyu@llu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Vaneet Sandhu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

